Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions
The authors discuss advanced sonocrystallization particle-engineering techniques for manufacturing mesoscopic particles.


Pharmaceutical Technology


16. X. Chen et al., "Rapid Dissolution of High-Potency Danazol Particles Produced by Evaporative Precipitation into Aqueous Solution," J. Pharm. Sci. 93 (7), 1867–1878 (2004).

17. X. Chen et al., "Preparation of Cyclosporine A Nanoparticles by Evaporative Precipitation into Aqueous Solution," Int. J. Pharm. 242 (1–2), 3–14 (2002).

18. University of Bath, Process for the Production of Particles, Patent WO/2004/073827, 2004.

19. R. Price, J.S. Kaerger, "Processing of Spherical Crystalline Particles via a Novel Solution Atomization and Crystallization by Sonication (SAXS) Technique," Pharm. Res. 21 (2), 372–381 (2004).

20. G. Ruecroft, "Power Ultrasound and Particle Engineering: Crystals for Drug Delivery and Formulation," Chim. Oggi 25 (3), 12–14 (2007).

21. G. Ruecroft, "Sound, Science, and Crystals: Improved Crystallization and Particle Engineering," Screening 2 34–36 (2007).

22. M. Hannay et al., "Overcoming the Challenges of Developing Combination Products in Different Inhalation Device Platforms," Respiratory Drug Del. 319 (2008).

23. Prosonix Limited, Process and Apparatus for Irradiating Fluids, Patent WO/2000/35579, 2000.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here